Guotaiqixing Biomedical International (S) PTE Ltd. v. Dai

CourtDistrict Court, S.D. New York
DecidedNovember 18, 2024
Docket1:24-cv-03142
StatusUnknown

This text of Guotaiqixing Biomedical International (S) PTE Ltd. v. Dai (Guotaiqixing Biomedical International (S) PTE Ltd. v. Dai) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Guotaiqixing Biomedical International (S) PTE Ltd. v. Dai, (S.D.N.Y. 2024).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK GUOTAIQIXING BIOMEDICAL INTERNATIONAL (S) PTE. LTD., Plaintiff, OPINION & ORDER – against – 24-cv-03142 (ER) XUEFENG DAI, Defendant. RAMOS, D.J.: In March 2024, Guotaiqixing Biomedical International (S) Pte. Ltd. (“GTQX”) filed this action in New York state court against Xuefeng “Eric” Dai for recognition of a foreign judgment pursuant to New York’s Uniform Foreign Country Money Judgment Act (“MJA”), N.Y. C.P.L.R. § 5301 et seq. A month later, in April 2024, Dai removed the action to federal court, where he has a pending action against numerous parties alleged to be in privity with GTQX for, inter alia, alleged violations of the Racketeer Influenced and Corrupt Organizations Act (“RICO”). Before the Court is GTQX’s motion to remand this action to the Supreme Court of State of New York, New York County, and for an award of attorneys’ fees and costs. Doc. 5. For the reasons set forth below, the motion is DENIED. I. FACTUAL AND PROCEDURAL BACKGROUND A. �e Parties GTQX is a company incorporated in Singapore and is a wholly owned subsidiary of Shenzhen Guotaiqixing Industry Investment Fund Management Centre LLP (the “Limited Partnership”). Doc. 1-4 at 355. Shenzhen Qianhai Nations Investment Management Co., Ltd. (“Nations Investment”) is the limited partner in the Limited Partnership. Id. Dai was born in the People’s Republic of China (“PRC”) and is currently a U.S. lawful permanent resident residing in Florida. Doc. 1-4 at 356. Dai lived in New York from 2015 until at least March 2020 and still conducts business in New York through his wholly owned corporation, Khan Funds Management America, Inc. (“Khan Funds”), which maintains its principal place of business in New York. Id. Khan Funds is a hedge fund focused on investments in biomedical and pharmaceutical companies. See id. at 300. Khan Funds became an “industry giant” and, at its height, ran fourteen hedge funds with assets totaling over one billion dollars. Id. Dai also wholly owns Beijing Khan Pharmaceutical Holdings Co., Ltd., the general partner in the Limited Partnership, and was formerly a director of GTQX with authority to make investment decisions. Id. at 355–57. B. �e Singapore Action In October 2020, GTQX filed a lawsuit in Singapore (“the Singapore Action”) against Dai and two of Dai’s employees alleging that they had unlawfully diverted millions of dollars from GTQX to entities that Dai controlled, including Khan Funds. See Doc. 1-4 at 358; see generally Doc. 1-1 at 60–106. Dai defended himself in that action from the United States. Doc. 1-5 ¶ 15; Doc. 11 at 9. In June 2023, the Singapore Court entered final judgment against Dai for $34,264,935.99 United States dollars and $290,153.97 Singapore dollars, plus pre- and post-judgment interest (“the Singapore Judgment”). Doc. 1-4 at 360–61, 370–71. �e Singapore Judgment included an order freezing Dai’s assets globally, including assets beneficially owned by Dai’s affiliated entities. Id. at 198–209. Dai asserts that GTQX’s filings in the Singapore Action were based on false allegations and relied on stolen and forged documents. Id. at 285. C. �e RICO Action Meanwhile, in April 2022, while the Singapore Action was pending, but before the Singapore Judgment was entered, Dai and Khan Funds filed an action in New York state court (“the RICO Action”) against various defendants, including Nations Investment and its parent company, Nations Technologies Inc. (“Nations Technologies”). See Khan Funds Management America, Inc. et al. v. Nations Technologies Inc. et al., No. 22-cv- 05055 (ER). Nations Technologies is a publicly traded Chinese company that is principally engaged in the design, manufacture, and distribution of integrated circuits. Doc. 1-5 ¶ 3. In the RICO Action, Dai and Khan Funds allege the defendants conspired to coerce them into stealing American technology for the PRC’s military. Doc. 1-5 at 4. �ey further allege that the defendants retaliated against Dai when he reported their scheme to the Federal Bureau of Investigation, including by filing the Singapore Action. Id. ¶¶ 88–109. �e pending RICO Action seeks, inter alia, an injunction forbidding the defendants from confirming or enforcing any judgment entered by the court in the Singapore Action—which was subsequently entered in June 2023—in the Unites States. See Doc. 1-5 at 11–12, 73. Although GTQX is not among the defendants in the RICO Action, it shares the same management with Nations Investment, Nations Technologies, and Nations Technologies (USA) Inc.—all of which are defendants in the RICO Action. Doc. 1 ¶ 13. In June 2022, the defendants removed the RICO Action to this Court on federal question grounds.1 Doc. 1 at 1–2. D. �e Instant Recognition Action In March 2024, two years after the RICO Action was filed, and nine months after the Singapore Judgment was entered, GTQX filed a Notice of Motion for Summary Judgment in Lieu of Complaint in New York state court, seeking recognition of the Singapore Judgment pursuant to the MJA (“the MJA Action”). Doc 1-1 at 2. �e Notice did not mention the RICO Action. See id. �e next month, in April 2024, Dai removed the MJA Action to this Court, arguing that the MJA Action is, in effect, a declaratory

1 Dai and Khan Funds filed an amended complaint on December 13, 2022. Doc. 1-5. judgment action, and that this Court has jurisdiction over the MJA Action because it is the “mirror image” of the RICO Action.2 Doc. 1. On May 24, 2024, GTQX filed the instant motion to remand to the Supreme Court of New York. Doc. 5. It claims that exigent circumstances—namely that Dai sold property in Florida in alleged violation of the Singapore Judgment—warranted filing the motion without a request for a pre-motion conference. Id. at 1. On June 11, 2024, Dai responded to the motion to remand. Doc. 11. On June 18, 2024, GTQX filed its reply, arguing that this Court lacks federal question jurisdiction. Id. II. LEGAL STANDARD �e federal removal statute provides that “any civil action brought in a [s]tate court of which the district courts of the United States have original jurisdiction[ ] may be removed by the defendant or the defendants, to the district court of the United States for the district and division embracing the place where such action is pending.” 28 U.S.C. § 1441(a). �e Second Circuit has established that “in light of the congressional intent to restrict federal court jurisdiction, as well as the importance of preserving the independence of state governments, federal courts construe the removal statute narrowly, resolving any doubts against removability.” Purdue Pharma L.P. v. Kentucky, 704 F.3d 208, 213 (2d Cir. 2013) (quoting Lupo v. Human Affairs International, Inc., 28 F.3d 269, 274 (2d Cir. 1994)). �e party seeking removal bears the burden of proving that the jurisdictional and procedural requirements of removal have been met. Mehlenbacher v. Akzo Novel Salt, Inc., 216 F.3d 291, 296 (2d Cir. 2000). However, “[i]f at any time before final judgment it appears that the district court lacks subject matter jurisdiction, the case shall be remanded.” 28 U.S.C. § 1447(c).

2 Dai also asserts diversity jurisdiction for the purpose of preserving the argument on appeal, but he concedes that current Second Circuit precedent forecloses his position. See Doc. 1 ¶ 9 (citing to Tagger v. Strauss Grp. Ltd.,

Related

Skelly Oil Co. v. Phillips Petroleum Co.
339 U.S. 667 (Supreme Court, 1950)
Public Serv. Comm'n of Utah v. Wycoff Co.
344 U.S. 237 (Supreme Court, 1952)
Abb Inc. v. Cooper Industries, LLC
635 F.3d 1345 (Federal Circuit, 2011)
Purdue Pharma L.P. v. Commonwealth of Kentucky
704 F.3d 208 (Second Circuit, 2013)
Naoko Ohno v. Yuko Yasuma
723 F.3d 984 (Ninth Circuit, 2013)
Canadian Imperial Bank of Commerce v. Saxony Carpet Co.
899 F. Supp. 1248 (S.D. New York, 1995)
Major League Baseball Properties, Inc. v. Price
105 F. Supp. 2d 46 (E.D. New York, 2000)
Federal Insurance Company v. TYCO INTERNATIONAL
422 F. Supp. 2d 357 (S.D. New York, 2006)
Hall v. Hall
584 U.S. 59 (Supreme Court, 2018)
Benjamin Tagger v. Strauss Grp. Ltd.
951 F.3d 124 (Second Circuit, 2020)

Cite This Page — Counsel Stack

Bluebook (online)
Guotaiqixing Biomedical International (S) PTE Ltd. v. Dai, Counsel Stack Legal Research, https://law.counselstack.com/opinion/guotaiqixing-biomedical-international-s-pte-ltd-v-dai-nysd-2024.